JonesTrading analyst Justin Walsh has reiterated their bullish stance on ACHV stock, giving a Buy rating yesterday.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Justin Walsh has given his Buy rating due to a combination of factors that highlight Achieve Life Sciences’ promising future. The company has demonstrated effective regulatory execution, particularly with cytisinicline, which has received a PDUFA target action date for smoking cessation. This regulatory progress is supported by the submission of all required safety data to the FDA, which strengthens confidence in the drug’s approval prospects.
Furthermore, cytisinicline has been awarded one of the first FDA Commissioner’s National Priority Vouchers for e-cigarette or vaping cessation, indicating a potential for expedited review processes in the future. The drug has shown a favorable safety profile with no serious adverse events reported, and its potential market penetration is significant, given the underutilization of smoking cessation products in the U.S. market. These factors, combined with the opportunity for label expansion into e-cigarette cessation, underpin the positive outlook for Achieve Life Sciences.
According to TipRanks, Walsh is a 5-star analyst with an average return of 17.8% and a 36.33% success rate. Walsh covers the Healthcare sector, focusing on stocks such as Achieve Life Sciences, Alto Neuroscience, Inc., and Perspective Therapeutics.
In another report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $12.00 price target.